

1972-74 Research Fellow of the Medical Foundation, Inc., Boston

1978-87 Pfizer Lecturer in Clinical Pharmacology
(at various institutions)

1980 Rawls-Palmer Progress in Medicine Award and Lecture,
American Society for Clinical Pharmacology and Therapeutics

1980 Clinical Pharmacology Unit Developmental Grant,
Pharmaceutical Manufacturers' Association Foundation,
Washington, D.C.

1981 Wellcome Visiting Professor in the Basic Medical Sciences
(the Burroughs Wellcome Fund and Federation of American Societies
for Experimental Biology),
East Carolina University School of Medicine, Greenville, N.C.

1983 Paul Ehrlich Visiting Professor of Clinical Pharmacology,
University of Miami School of Medicine

1984 Sterling Visiting Professor,
Boston University School of Medicine

1985 The McKeen Cattell Award,
(with Drs. O. Bellmann, H.R. Ochs, and M. Knüchel)
American College of Clinical Pharmacology

1988 T. George Bidder Distinguished Lectureship in Psychopharmacology,
University of California at Los Angeles

1997 Pfizer Visiting Professor of Clinical Pharmacology,
Morehouse University School of Medicine, Atlanta, GA

2001 Distinguished Service Award,
American College of Clinical Pharmacology

2002 Distinguished Investigator Award,
American College of Clinical Pharmacology

2005 Research Achievement Award in Clinical Sciences,
American Association of Pharmaceutical Scientists

2013 Outstanding Speaker Award,
American Association for Clinical Chemistry

2015 Distinguished Faculty Award,
Tufts University School of Medicine

2016 Award in Excellence in Clinical Pharmacology,
Pharmaceutical Research and Manufacturers of America Foundation

2016 Man of Good Conscience Award,
Association of Women Psychiatrists

Certification

1991 American Board of Clinical Pharmacology, Inc.

Editorial Boards

Journal of Clinical Psychopharmacology (Co-Editor-in-Chief)

Clinical Pharmacology in Drug Development (Editor-in-Chief)

Journal of Clinical Pharmacology

Xenobiotica

Neuropsychopharmacology (1986-1990)

Drug Investigation

Drugs and Aging

Pharmacology and Toxicology

Drugs and Therapy Perspectives

Professional Societies

American Society for Clinical Investigation (Emeritus)

American Society for Pharmacology and Experimental Therapeutics

American Federation for Clinical Research

American Society for Clinical Pharmacology and Therapeutics
Board of Directors, 1983-85

American College of Clinical Pharmacology
Board of Regents, 1981-85, 1987-91;
Honorary Regent, 1994-;
President-Elect, 1994-1996;
President, 1996-1998

American College of Neuropsychopharmacology (Fellow) (1974-2011)

International Society for the Study of Xenobiotics

British Pharmacological Society

ORIGINAL RESEARCH ARTICLES

1. Tursky B, Greenblatt DJ: Local vascular and thermal changes that accompany electric shock. Psychophysiology 3:371-380, 1967.
2. Greenblatt DJ, DiMascio A, Messier M, Stotsky B: Magnesium pemoline and job performance in mentally handicapped workers. Clinical Pharmacology and Therapeutics 10:530-533, 1969.
3. Greenblatt DJ, Tursky B: Local vascular and impedance changes induced by electric shock. American Journal of Physiology 216:712-718, 1969.
4. Tursky B, Greenblatt DJ, O'Connell DN: Electrocutaneous threshold changes produced by electric shock. Psychophysiology 7:490-498, 1970.
5. Greenblatt DJ, Shader RI: Psychopharmacologic management of anxiety in the cardiac patient. Psychiatry in Medicine 2:490-498, 1970.
6. Greenblatt DJ, Shader RI: Meprobamate: a study of irrational drug use. American Journal of Psychiatry 127:1297-1303, 1971.
7. Greenblatt DJ, Shader RI: The clinical choice of sedative-hypnotics. Annals of Internal Medicine 77:91-100, 1972.
8. Greenblatt DJ, Shader RI: On the psychopharmacology of beta adrenergic blockade. Current Therapeutic Research 14:615-625, 1972.
9. Greenblatt DJ, Koch-Weser J: Adverse reactions to spironolactone: a report from the Boston Collaborative Drug Surveillance Program. Journal of the American Medical Association 225:40-43, 1973.
10. Greenblatt DJ, Shader RI: Anticholinergics. New England Journal of Medicine 288:1215-1219, 1973.
11. Greenblatt DJ, Koch-Weser J: Adverse reactions to propranolol in hospitalized medical patients: a report from the Boston Collaborative Drug Surveillance Program. American Heart Journal 86:478-484, 1973.
12. Greenblatt DJ, Koch-Weser J: Adverse reactions to intravenous diazepam: a report from the Boston Collaborative Drug Surveillance Program. American Journal of Medical Sciences 266:261-266, 1973.
13. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW: Evaluation of digoxin bioavailability in single-dose studies. New England Journal of Medicine 289:651-654, 1973.
14. Greenblatt DJ, Koch-Weser J: Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston Collaborative Drug Surveillance Program. Drugs 7:118-129, 1974.
15. Greenblatt DJ, Shader RI: Drug abuse and the emergency room physician. American Journal of Psychiatry 131:559-562, 1974.
16. Duhme DW, Greenblatt DJ, Koch-Weser J: Reduction of digoxin toxicity associated with measurement of serum levels: a report from the Boston Collaborative Drug Surveillance Program. Annals of Internal Medicine 80:516-519, 1974.
17. Koch-Weser J, Duhme DW, Greenblatt DJ: Influence of serum digoxin concentration measurements on frequency of digitoxicity. Clinical

18. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW: Intravenous digoxin as a bioavailability standard: slow infusion and rapid injection. Clinical Pharmacology and Therapeutics 15:510-513, 1974.
19. Greenblatt DJ, Koch-Weser J: Oral contraceptives and hypertension: a report from the Boston Collaborative Drug Surveillance Program. Obstetrics and Gynecology 44:412-417, 1974.
20. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW: Equivalent bioavailability from digoxin elixir and rapid-dissolution tablets. Journal of the American Medical Association 229:1774-1776, 1974.
21. Greenblatt DJ, Shader RI, Koch-Weser J. Pharmacokinetic determinants of the response to single doses of chlordiazepoxide. American Journal of Psychiatry 131:1395-1397, 1974.
22. Greenblatt DJ, Koch-Weser J: Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program. European Journal of Clinical Pharmacology 7:259-262, 1974.
23. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW: Bioavailability of digoxin tablets and elixir in the fasting and postprandial states. Clinical Pharmacology and Therapeutics 16:444-448, 1974.
24. Greenblatt DJ, Shader RI, Koch-Weser J, Franke K: Slow absorption of intramuscular chlordiazepoxide. New England Journal of Medicine 291:1116-1118, 1974.
25. Greenblatt DJ, Duhme DW, Koch-Weser J, Smith TW: Comparison of one- and six-day urinary digoxin excretion in single-dose bioavailability studies. Clinical Pharmacology and Therapeutics 16:813-816, 1974.
26. Greenblatt DJ, Shader RI: Benzodiazepines. New England Journal of Medicine 291:1011-1015, 1239-1241, 1974.
27. Greenblatt DJ, Shader RI, Koch-Weser J: Flurazepam hydrochloride. Clinical Pharmacology and Therapeutics 17:1-14, 1975.
28. Sokol GH, Greenblatt DJ, Littman P, Franke K, Koch-Weser J: Chlordiazepoxide metabolism in mice following hepatic irradiation. Pharmacology 13:248-251, 1975.
29. Greenblatt DJ, Shader RI, Koch-Weser J: Psychotropic drug use in the Boston area: a report from the Boston Collaborative Drug Surveillance program. Archives of General Psychiatry 32:518-521, 1975.
30. Shader RI, Greenblatt DJ, Salzman C, Kochansky GE, Harmatz JS: Benzodiazepines: safety and toxicity. Diseases of the Nervous System 36(No.5,Sect.2):23-26, (May) 1975.
31. Greenblatt DJ, Shader RI, Koch-Weser J: Pharmacokinetics in clinical medicine: oxazepam versus other benzodiazepines. Diseases of the Nervous System 36(No.5, Sect.2):6-13, (May) 1975.
32. Greenblatt DJ, Shader RI, Koch-Weser J: Flurazepam hydrochloride, a benzodiazepine hypnotic. Annals of Internal Medicine 83:237-241, 1975.
33. Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J: Pharmacokinetics of digoxin in normal subjects after intravenous bolus

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.